Literature DB >> 64469

Structure of tetanus toxin. II. Toxin binding to ganglioside.

T B Helting, O Zwisler, H Wiegandt.   

Abstract

The interaction between tetanus toxin and ganglioside containing 2 N-acetylneuraminic acid residues linked in sequence to one another has been investigated using a new method involving radioactively labeled ganglioside and tetanus toxin adsorbed to Sephadex matrix. Binding between the two components was demonstrated, and it was calculated that in the nanomolar concentration range, tetanus toxin becomes half-saturated at about 5 X 10(-8) M concentration of ganglioside. Removal of the ceramide portion from the ganglioside resulted in the complete loss of binding activity, whereas removal of the terminal N-acetylneuraminic acid residue from the intact ganglioside had no effect. Among the fragments derived from tetanus toxin (Helting, T. B., and Zwisler, O. (1977) J. Biol. Chem. 252, 187-193), only the heavy chain polypeptide exhibited a binding activity of the same order of magnitude as that observed for the native toxin. The light chain polypeptide showed no interaction with ganglioside and among the fragments derived from the toxin by digestion with papain, only Fragment C, at a high protein concentration, displayed marginal binding activity. Using monovalent antibodies directed against specific regions of the tetanus toxin molecule, it was demonstrated that antibodies directed against Fragment C uniquely interfere with the binding process. Anti-light chain serum was ineffective, as well as antitetanus toxoid serum previously absorbed with Fragment C. It is concluded that the binding site for ganglioside is located on the heavy chain portion of tetanus toxin, possibly in or near the region comprised by Fragment C.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 64469

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin.

Authors:  K Dobrenis; A Joseph; M C Rattazzi
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

2.  Synthesis of tetanus toxin fragment C in insect cells by use of a baculovirus expression system.

Authors:  I G Charles; B C Rodgers; A J Makoff; S N Chatfield; D E Slater; N F Fairweather
Journal:  Infect Immun       Date:  1991-05       Impact factor: 3.441

3.  Isolation, purification, and characterization of fragment B, the NH2-terminal half of the heavy chain of tetanus toxin.

Authors:  M Matsuda; D L Lei; N Sugimoto; K Ozutsumi; T Okabe
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

Review 4.  Tetanus toxin.

Authors:  B Bizzini
Journal:  Microbiol Rev       Date:  1979-06

5.  Relation between protective potency and specificity of antibodies in sera of tetanus immunized individuals.

Authors:  M German-Fattal; A German; B Bizzini
Journal:  Eur J Epidemiol       Date:  1987-06       Impact factor: 8.082

6.  Antibodies against the light chain of tetanus toxin in human sera.

Authors:  C S Lin; W H Habig; M C Hardegree
Journal:  Infect Immun       Date:  1985-07       Impact factor: 3.441

7.  A Heterologous Reporter Defines the Role of the Tetanus Toxin Interchain Disulfide in Light-Chain Translocation.

Authors:  Madison Zuverink; Chen Chen; Amanda Przedpelski; Faith C Blum; Joseph T Barbieri
Journal:  Infect Immun       Date:  2015-04-20       Impact factor: 3.441

8.  Characterization of recombinant tetanus toxin derivatives suitable for vaccine development.

Authors:  D Figueiredo; C Turcotte; G Frankel; Y Li; O Dolly; G Wilkin; D Marriott; N Fairweather; G Dougan
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

Review 9.  Clostridium botulinum neurotoxin.

Authors:  H Sugiyama
Journal:  Microbiol Rev       Date:  1980-09

10.  Topographic studies of gangliosides of intact synaptosomes from rat brain cortex.

Authors:  B L Hungund; S P Mahadik
Journal:  Neurochem Res       Date:  1981-02       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.